All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
This is the second episode in a series of podcasts following the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, on the topic of circulating tumor DNA (ctDNA) in the management of lymphoma. The Lymphoma hub asked Reid Merryman, Dana-Farber Cancer Institute, Boston, US, Can circulating tumor DNA (ctDNA) help inform on the suitability of autologous stem cell transplantation (auto-SCT) in patients with diffuse large B-cell lymphoma (DLBCL)?
Can ctDNA help inform on the suitability of auto-SCT in patients with DLBCL?
Merryman firstly outlines a strategy for using ctDNA as a prognostic biomarker in patients with DLBCL undergoing auto-STC. Merryman provides supporting data from a study evaluating the prognostic value of ctDNA using an immunoglobulin-based next-generation sequencing technique in patients with DLBCL undergoing auto-STC. He highlights the poor 5-year progression-free survival in patients who were ctDNA-positive within an apheresis stem cell sample. He concludes by outlining the importance of ctDNA as a powerful predictor of relapse; in the future, this tool could be used to guide treatment in patients who are ctDNA-positive.
For the first episode in this series click here.
For the third episode in this series click here.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox